- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Vanta Bioscience Ltd — Board Meeting, 30-05-2026: Board Meeting
30-05-2026 | 08:25 pm
30-05-2026 | 08:25 pm
Vanta Bioscience board cleared FY26 & H2 financial results. MD Dopesh Raja Mulakala re-appointed for 3 years (shareholder approval pending). Auditors gave a clean report. Subsidiary assets stood at ₹3.94 Cr, with H2 & FY26 net losses of ₹0.01 Cr each.
No comments yet. Be the first to comment!